The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Market Value Expansion Is Expected For The Pruritus Therapeutic Market Over The Forecast Period?
The pruritus therapeutic market has demonstrated substantial expansion recently. Projections indicate its expansion from $15.38 billion in 2025 to $16.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. This historical growth can be attributed to factors such as the rising incidence of dermatological and systemic conditions, increased utilization of antihistamines and corticosteroids, the development of outpatient dermatology services, heightened patient understanding of disorders associated with itching, and the availability of a variety of treatment approaches.
The pruritus therapeutic market is anticipated to experience robust growth in the coming years, with projections indicating an expansion to $24.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.4%. This projected growth during the forecast period is fueled by increasing investment in novel itch-modulating therapies, a heightened focus on personalized pruritus treatment, the broadening of biologic and immunomodulatory drug pipelines, rising demand for non-steroidal therapies, and intensified clinical research activity. Prominent trends expected in this period include the increasing development of targeted antipruritic drugs, a growing adoption of combination drug therapies, an elevated focus on managing disease-specific pruritus, the expansion of advanced topical formulations, and an enhanced emphasis on achieving long-term symptom relief.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9925&type=smp
What Important Drivers Are Powering The Pruritus Therapeutic Market Growth?
The growing prevalence of chronic kidney disease is expected to propel the growth of the pruritus therapeutic market in the coming years. Chronic Kidney Disease (CKD) is a long-term disorder characterized by a gradual decline in kidney function, classified into five severity levels. Pruritus, commonly known as itching, is a frequent symptom associated with chronic kidney disease (CKD), though its specific underlying mechanisms are still being researched. For instance, in June 2023, according to Kidney Research UK, a UK-based charitable organization, an estimated 7.19 million people in the UK were affected by chronic kidney disease in 2023, representing more than 10% of the UK population, with this number projected to increase to 7.61 million people by 2033. Consequently, the increasing incidence of chronic kidney disease is a significant driver for the pruritus therapeutic market.
How Are Different Segment Groups Identified Within The Pruritus Therapeutic Market?
The pruritus therapeutic market covered in this report is segmented –
1) By Type: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, Others Types
2) By Disease Type: Atopic Dermatitis Or Eczema, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
3) By Application: External Use, Oral, Injection
4) By End Use: Hospitals, Clinics, Other Uses
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetics: Topical Local Anesthetics, Injectable Local Anesthetics
4) By Counterirritants: Menthol-Based Products, Camphor-Based Products
5) By Immunosuppressants: Systemic Immunosuppressants, Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus, Pimecrolimus
7) By Other Types: Antidepressants, Phototherapy Treatments, Biologic And Targeted Therapies
Which Trends Are Guiding The Development Of The Pruritus Therapeutic Market?
Leading companies in the prurigo nodularis treatment market are concentrating on developing advanced therapies, such as monoclonal antibodies, to precisely target immune pathways and offer more effective symptom relief. Monoclonal antibodies are artificial molecules crafted to imitate the immune system’s capacity to combat harmful pathogens, including viruses. For example, in August 2024, Galderma, a pharmaceutical company based in Switzerland, announced that the U.S. Food and Drug Administration (FDA) had approved Nemluvio (nemolizumab) for the treatment of adult patients with prurigo nodularis. This approval was granted based on positive outcomes from the OLYMPIA clinical trials, where Nemluvio showed considerable improvement in both itch intensity and skin nodules. This particular treatment specifically targets IL-31 signaling, addressing a crucial factor contributing to prurigo nodularis symptoms.
Which Firms Are Competing In The Pruritus Therapeutic Market?
Major companies operating in the pruritus therapeutic market are Astellas Pharma Inc., Bristol Myers Squibb Company, Cipla Inc., Eli Lilly And Company, Galderma Laboratories LP, GlaxoSmithKline plc, Merck And Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Abbott Laboratories, Almirall SA, Eisai Co. Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Chemicals Ltd., Cara Therapeutics Inc., EPI Health LLC, AbbVie Inc., Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Huapont Life Sciences Co. Ltd., LEO Pharma AS, MC2 Therapeutics Ltd., Novan Inc., Trevi Therapeutics Inc., UCB SA, Viatris Inc., Teva Pharmaceutical Industries Ltd.
Access The Complete Pruritus Therapeutic Market Report:
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
Which Region Commands The Largest Share Of The Pruritus Therapeutic Market?
North America was the largest region in the pruritus therapeutic market in 2025. The regions covered in the pruritus therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Pruritus Therapeutic Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=9925&type=smp
Browse Through More Reports Similar to the Global Pruritus Therapeutic Market 2026, By The Business Research Company
Pruritus Therapeutics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report
Tinea Pedis Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/tinea-pedis-treatment-global-market-report
Vitiligo Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/vitiligo-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
